FMT Versus Antimicrobials for Initial Treatment of Recurrent CDI
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine the safety and efficacy of Fecal Microbiota
Transplant (FMT) for the treatment of the recurrence of Clostridium difficile infection (CDI)
as compared to standard antibiotic therapy. Patients who have tested positive for CDI within
90 days of an admission for relapse of CDI will be approached to participate in this
open-label, randomized controlled trial. Patients will either be randomized to the
intervention group (receive FMT via retention enema) or the control group (receive
antimicrobials targeting CDI).